Evaluation of antibody levels over 3years after 23-valent pneumococcal polysaccharide vaccination in patients with pulmonary diseases receiving steroids and immunosuppressive agents

Akamatsu, Taisuke; Inui, Naoki; Kusagaya, Hideki; Nakamura, Yutaro; Suda, Takafumi; Chida, Kingo

doi:10.1016/j.clinbiochem.2014.11.005

Cited by 5 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown variation as early as 6 months to 5 years [ 44 ]. A 2015 study of subjects with pulmonary diseases receiving immunosuppressive therapy and steroids found that elevated antibody levels persist for 3 years after vaccination [ 45 ]. The study concluded that patients on immunosuppressive medication should be revaccinated at a period of 3 years.…”

Section: Secondary Immunodeficiencymentioning

confidence: 99%

Pneumococcal Vaccination in Immunocompromised Hosts: An Update

2021

View full text Add to dashboard Cite

Infections with the pathogen, Streptococcus pneumoniae, are a common cause of morbidity and mortality worldwide. It particularly affects those at the extremes of age and immunocompromised individuals. Preventing pneumococcal disease is paramount in at risk individuals, and pneumococcal vaccination should be offered. Here, we discuss the role of pneumococcal vaccination in specific groups of immunocompromised hosts.

show abstract

Section: Secondary Immunodeficiencymentioning

confidence: 99%

Pneumococcal Vaccination in Immunocompromised Hosts: An Update

2021

View full text Add to dashboard Cite

show abstract

“…They reported that anti-pneumococcal antibody levels following vaccination were similar to the control group (who were not being treated with immunosuppressive therapy). They concluded that PPSV23 is effective in the patients, even though they are undergoing systemic steroid and/or immunosuppressive therapy [63]. In addition, Kuronuma et al documented that both PCV13 and PPSV23 induced anti-pneumococcal antibodies in patients with ILD receiving systemic steroid and/or immunosuppressive therapy [64].…”

Section: Interstitial Lung Diseasementioning

confidence: 99%

Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults

Asai

Mikamo

2021

Microorganisms

View full text Add to dashboard Cite

Pneumococcal disease is one of the most common and severe vaccine-preventable diseases (VPDs). Despite the advances in antimicrobial treatment, pneumococcal disease still remains a global burden and exhibits a high mortality rate among people of all ages worldwide. The immunization program of the pneumococcal conjugate vaccine (PCV) in children has decreased pneumococcal disease incidence in several countries. However, there are several problems regarding the pneumococcal vaccine, such as indications for immunocompetent persons with underlying medical conditions with a risk of pneumococcal disease, the balance of utility and cost, i.e., cost-effectiveness, vaccine coverage rate, serotype replacement, and adverse events. Especially for individuals aged 19–64 at risk of pneumococcal disease, physicians and vaccine providers should make a rational decision whether the patients should be vaccinated or not, since there is insufficient evidence supporting it. We describe this review regarding topics and problems regarding pneumococcal vaccination from the clinician’s point of view.

show abstract

The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis

Aalst

Langedijk

Spijker

et al. 2018

Vaccine

View full text Add to dashboard Cite

The findings of our systematic review indicate that, in patients treated with immunosuppressive medication and compared to controls, the initial serologic response to pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV) are impaired. Moreover, this impaired response was more profound after PCV than after PPSV. We hypothesize that the immunosuppressive medication mainly compromises the cellular immunity, explaining the more severely reduced response rate to PCV (which induces a T-cell dependent immune response), compared to PPSV. Treatment with TNFα blocking agents was associated with a more favorable response, compared to patients treated with other immunosuppressive medication. Targeted research applying uniform correlates of protection is needed to bridge the knowledge gap in vaccination immunology in this patient group. PROSPERO registration: CRD42017058364.

show abstract

Evaluation of antibody levels over 3years after 23-valent pneumococcal polysaccharide vaccination in patients with pulmonary diseases receiving steroids and immunosuppressive agents

Cited by 5 publications

References 22 publications

Pneumococcal Vaccination in Immunocompromised Hosts: An Update

Pneumococcal Vaccination in Immunocompromised Hosts: An Update

Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults

The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis

Contact Info

Product

Resources

About